Anti-L1CAM [UJ127.11]
Invented by Dr JOHN KEMSHEAD from SHIRE PHARMACEUTICALS
Invented at Institute Of Child Health
- Datasheet
- References (15)
- Inventor Info
Info
| Catalogue Number | 151178 |
| Applications | ELISA FACS IHC IF IP WB |
| Antigen/Gene or Protein Targets | L1 cell adhesion molecule (L1CAM; CD171) |
| Synonyms | CAML1, HSAS1, Hyd, L1 Cell Adhesion Molecule, L1-NCAM, MASA, MIC5, NCAM-L1, Nerve-growth factor-inducible large external glycoprotein, Neural cell adhesion molecule L1, NILE, S10, SPG1 |
| Reactivity | Human and Mouse |
| Relevance |
Monoclonal antibody capable of differentiating between brain tumours of neural origin rather than glial origin. Background and Research Application Anti-L1CAM (UJ127.11) recognises L1 cell adhesion molecule (L1CAM), a cell-surface glycoprotein of 220-240kDa (doublet) and member of the neural adhesion molecule family of the immunoglobulin superfamily. UJ127.11 may be useful in the diagnosis of embryonic tumours (e.g. neuroblastoma) or for the purpose of bone marrow purging. Studies on normal foetal and adult tissues show that UJ127:11 recognises antigen restricted in its expression to cells of neural rather than glial origin. Neural tumours such as neuroblastoma, medulloblastoma, schwannomas and ganglioglioma bind the monoclonal antibody whereas malignancies originating from glial cells do not bind UJ 127:11 – this allows for diagnosis of the origin of brain tumour. This antibody has little cross-reactivity with tissues outside of the neuroectoderm. L1CAM is implicated in the development of the nervous system and its expression is restricted to tissues arising from the neuroectoderm. L1CAM is present on tumours of neuroectodermal and glial origin (e.g. neuroblastoma and schwannomas). L1CAM also plays an important role in axon growth, fasciculation, neural migration and in mediating neuronal differentiation. Expression of L1 protein is restricted to tissues arising from neuroectoderm. |
| Host | Mouse |
| Immunogen | Homogenous suspension of 16 week human foetal brain. |
| Immunogen UniProt ID | P32004 |
| Positive Control | Frozen mouse E16.5 lung sections (IHC), Cell lines TR 14, LAN-1, CHP 100, CHP212, CHP126 ( Neuroblastomas or Schwannomas) (IF), M5 melanoma cells or human foetal brain (WB) |
| Subclass | IgG1 kappa |
| Molecular Weight (kDa) | 220-240kDa |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Strain | Balb/c |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest UJ 127:11 has proved useful in the diagnosis of metastatic spread of neuroblastoma to bone marrow, as the antibody does not react with normal haemopoietic cells from foetal, paediatric or adult bone marrow. Anti-L1CAM recognises antigen in both reducing and non-reducing conditions. This antibody was made via avoiding immunizing mice with human neuroblastoma tumour, which is often calcified and necrotic, and instead chose fresh human foetal brain as an immunogen, as many reports have described the expression of foetal antigens on human tumour cells. Frozen sections of adult cerebellum, temporal lobe, adrenal medulla and nerve plexi in the colon and oesophagus were found to contain cells expressing the UJ127:11 antigen, thus anti-UJ127:11 only binds to tissue of neuroectodermal origin. This antibody does not bind to any pre-B, B, T, on-B non-T, promyelocytic or myeloid leukemic cell line. Cellular Localization: Cell surface Suggested Dilutions: Flow Cytometry (0.5-1ug/million cells); Immunofluorescence (1-2ug/ml); Concentration 1mg/ml as standard |
| Research Area | Adhesion, Cell Signaling & Signal Transduction, Neurobiology |
References: 15 entries
Maten et al. 2019. Int J Mol Sci. 20(17):. PMID: 31455004.
Pace et al. 2019. Int J Mol Sci. 20(16):. PMID: 31426278.
Stevers et al. 2019. Mod Pathol. 32(1):88-99. PMID: 30171198.
Wang et al. 2018. Neurobiol Dis. 116:53-59. PMID: 29705185.
Er et al. 2018. Nat Cell Biol. 20(8):966-978. PMID: 30038252.
Zaatiti et al. 2018. Int J Oncol. 52(3):787-803. PMID: 29328367.
Wood et al. 2018. Brain Pathol. 28(2):192-202. PMID: 28960623.
Fontanals-Cirera et al. 2017. Mol Cell. 68(4):731-744.e9. PMID: 29149598.
Agrawal et al. 2017. Cancer Cell. 31(6):804-819.e7. PMID: 28609658.
Lund et al. 2015. PLoS One. 10(4):e0123684. PMID: 25860483.
IF
Matsuda et al. 2013. J Proteomics. 85:1-11. PMID: 23612463.
ELISA IP WB
Morales et al. 2012. Mol Cell Proteomics. 11(6):M111.011973. PMID: 22186713.
Heiz et al. 2004. J Biol Chem. 279(30):31149-56. PMID: 15151998.
Patel et al. 1990. Biochem Soc Trans. 18(2):274. PMID: 2379713.
Kemshead et al. 1983. Int J Cancer. 31(2):187-95. PMID: 6826247.
Add a reference
References: 15 entries
Maten et al. 2019. Int J Mol Sci. 20(17):. PMID: 31455004.
Pace et al. 2019. Int J Mol Sci. 20(16):. PMID: 31426278.
Stevers et al. 2019. Mod Pathol. 32(1):88-99. PMID: 30171198.
Wang et al. 2018. Neurobiol Dis. 116:53-59. PMID: 29705185.
Er et al. 2018. Nat Cell Biol. 20(8):966-978. PMID: 30038252.
Zaatiti et al. 2018. Int J Oncol. 52(3):787-803. PMID: 29328367.
Wood et al. 2018. Brain Pathol. 28(2):192-202. PMID: 28960623.
Fontanals-Cirera et al. 2017. Mol Cell. 68(4):731-744.e9. PMID: 29149598.
Agrawal et al. 2017. Cancer Cell. 31(6):804-819.e7. PMID: 28609658.
Lund et al. 2015. PLoS One. 10(4):e0123684. PMID: 25860483.
IF
Matsuda et al. 2013. J Proteomics. 85:1-11. PMID: 23612463.
ELISA IP WB
Morales et al. 2012. Mol Cell Proteomics. 11(6):M111.011973. PMID: 22186713.
Heiz et al. 2004. J Biol Chem. 279(30):31149-56. PMID: 15151998.
Patel et al. 1990. Biochem Soc Trans. 18(2):274. PMID: 2379713.
Kemshead et al. 1983. Int J Cancer. 31(2):187-95. PMID: 6826247.
Add a reference
